Terms ending in 2039
Every in-force patent on Purdue Pharma L.P.'s record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,576,913 | Sleep Disorder Treatment and Prevention In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,171,762 | Sleep Disorder Treatment and Prevention In force · Low confidence | Knoa Pharma LLC | In force | Low confidence | |
| US 11,401,345 | Humanized Antibodies Targeting Human Tissue Factor In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 11,576,899 | Tinostamustine for Use in Treating Sarcoma In force · High confidence | Knoa Pharma LLC | In force | High confidence | |
| US 12,161,754 | Abuse Deterrent Morphine Sulfate Dosage Forms In force · High confidence | Purdue Pharma L.P. | In force | High confidence | |
| US 11,857,547 | Compositions and Methods for Opioid Antagonist Delivery In force · High confidence | Purdue Pharma L.P. | In force | High confidence | |
| US 11,865,112 | Compositions and Methods for Opioid Antagonist Delivery In force · High confidence | Purdue Pharma L.P. | In force | High confidence |
7 of 7 patents shown. Soonest term end first, then patent number.
5 of these are in force and held by Purdue Pharma L.P..
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.